



NDA 207931/S006

SUPPLEMENT APPROVAL

AbbVie Inc.
Attention: Viraj Gandhi, MS MBA, RAC
Senior Manager, Regulatory Affairs
One North Waukegan Road
Dept. PA 72/Bldg. AP30
North Chicago, Illinois 60064

Dear Mr. Gandhi:

Please refer to your Supplemental New Drug Application (sNDA) dated and received April 27, 2016, and your amendments, submitted under section 505(b) of the Federal Food, Drug, and Cosmetic Act (FDCA) for TECHNIVIE (ombitasvir, paritaprevir and ritonavir)12.5 mg/75 mg/50 mg tablets, for oral use.

We also refer to our approval letter dated February 24, 2017 which contained the following error: Content changes to the MEDICATION GUIDE that is different from earlier approved labeling on February 14, 2017, specifically in the following section:

“Do not take TECHNIVIE if you”

February 14, 2017 approved label	<ul style="list-style-type: none"> colchicine (Colcrys®) in patients who have certain kidney or liver problems
February 27, 2017 approved label	<ul style="list-style-type: none"> colchicine (Colcrys®)
February 14, 2017 approved label	<ul style="list-style-type: none"> carbamazepine (Carbatrol®, Epitol®, Equetro®, Tegretol®, TEGRETOL-XR®, TERIL®)
February 27, 2017 approved label	<ul style="list-style-type: none"> carbamazepine (Carbatrol®, Epitol®, Equetro®, Tegretol®)
February 14, 2017 approved label	<ul style="list-style-type: none"> Propulsid®
February 27, 2017 approved label	<ul style="list-style-type: none"> Propulsid
February 14, 2017 approved label	<ul style="list-style-type: none"> Dronedarone
February 27, 2017 approved label	<ul style="list-style-type: none"> Dronederone

This replacement approval letter incorporates the correction of the error. The effective approval date will remain February 24, 2017, the date of the original approval letter.

This Prior Approval supplemental new drug application provides revisions to labeling for the addition of the treatment of chronic hepatitis C virus (HCV) genotype 4 (GT4) infected patients with compensated cirrhosis based on results from Study M11-665.

APPROVAL & LABELING

We have completed our review of this supplemental application, as amended. It is approved, effective on the date of this letter, for use as recommended in the enclosed, agreed-upon labeling text.

WAIVER OF HIGHLIGHTS SECTION

We are waiving the requirements of 21 CFR 201.57(d)(8) regarding the length of Highlights of prescribing information. This waiver applies to all future supplements containing revised labeling unless we notify you otherwise.

CONTENT OF LABELING

As soon as possible, but no later than 14 days from the date of this letter, submit the content of labeling [21 CFR 314.50(l)] in structured product labeling (SPL) format using the FDA automated drug registration and listing system (eLIST), as described at <http://www.fda.gov/ForIndustry/DataStandards/StructuredProductLabeling/default.htm>. Content of labeling must be identical to the enclosed labeling (text for the package insert and Medication Guide), with the addition of any labeling changes in pending “Changes Being Effected” (CBE) supplements, as well as annual reportable changes not included in the enclosed labeling.

Information on submitting SPL files using eList may be found in the guidance for industry titled “SPL Standard for Content of Labeling Technical Qs and As at <http://www.fda.gov/downloads/DrugsGuidanceComplianceRegulatoryInformation/Guidances/UCM072392.pdf>.”

The SPL will be accessible from publicly available labeling repositories.

Also within 14 days, amend all pending supplemental applications that include labeling changes for this NDA, including CBE supplements for which FDA has not yet issued an action letter, with the content of labeling [21 CFR 314.50(l)(1)(i)] in MS Word format, that includes the changes approved in this supplemental application, as well as annual reportable changes and annotate each change. To facilitate review of your submission, provide a highlighted or marked-up copy that shows all changes, as well as a clean Microsoft Word version. The marked-up copy should provide appropriate annotations, including supplement number(s) and annual report date(s).

REQUIRED PEDIATRIC ASSESSMENTS

Under the Pediatric Research Equity Act (PREA) (21 U.S.C. 355c), all applications for new active ingredients, new indications, new dosage forms, new dosing regimens, or new routes of administration are required to contain an assessment of the safety and effectiveness of the product for the claimed indication(s) in pediatric patients unless this requirement is waived, deferred, or inapplicable.

Because none of these criteria apply to your application, you are exempt from this requirement.

PROMOTIONAL MATERIALS

You may request advisory comments on proposed introductory advertising and promotional labeling. To do so, submit the following, in triplicate, (1) a cover letter requesting advisory comments, (2) the proposed materials in draft or mock-up form with annotated references, and (3) the package insert(s) to:

OPDP Regulatory Project Manager
Food and Drug Administration
Center for Drug Evaluation and Research
Office of Prescription Drug Promotion (OPDP)
5901-B Ammendale Road
Beltsville, MD 20705-1266

Alternatively, you may submit a request for advisory comments electronically in eCTD format. For more information about submitting promotional materials in eCTD format, see the draft Guidance for Industry (available at:

<http://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/UCM443702.pdf>).

You must submit final promotional materials and package insert(s), accompanied by a Form FDA 2253, at the time of initial dissemination or publication [21 CFR 314.81(b)(3)(i)]. Form FDA 2253 is available at

<http://www.fda.gov/downloads/AboutFDA/ReportsManualsForms/Forms/UCM083570.pdf>.

Information and Instructions for completing the form can be found at

<http://www.fda.gov/downloads/AboutFDA/ReportsManualsForms/Forms/UCM375154.pdf>. For more information about submission of promotional materials to the Office of Prescription Drug Promotion (OPDP), see <http://www.fda.gov/AboutFDA/CentersOffices/CDER/ucm090142.htm>.

REPORTING REQUIREMENTS

We remind you that you must comply with reporting requirements for an approved NDA (21 CFR 314.80 and 314.81).

If you have any questions, call Alicia Moruf, PharmD, MPH, Regulatory Project Manager, at (301) 796-3953.

Sincerely,

{See appended electronic signature page}

Debra Birnkrant, MD
Director
Division of Antiviral Products
Office of Antimicrobial Products
Center for Drug Evaluation and Research

ENCLOSURE(S):
Content of Labeling

This is a representation of an electronic record that was signed electronically and this page is the manifestation of the electronic signature.

/s/

JEFFREY S MURRAY
02/24/2017